iRhythm Technologies (NASDAQ:IRTC) Announces Earnings Results, Beats Expectations By $0.21 EPS

Posted by Geri Gentry on May 2nd, 2026

iRhythm Technologies (NASDAQ:IRTC – Get Free Report) released its earnings results on Thursday. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.21, FiscalAI reports. The company had revenue of $199.39 million during the quarter, compared to analysts’ expectations of $194.11 million. iRhythm Technologies had a negative net margin of 3.53% and a negative return on equity of 10.97%. iRhythm Technologies’s revenue for the quarter was up 25.6% on a year-over-year basis. During the same period last year, the business earned ($0.97) EPS.

Here are the key takeaways from iRhythm Technologies’ conference call:

Strong Q1 financials — revenue of $199.4M (+25.7% YoY), adjusted EBITDA margin 7.1% (up 880 bps), raised 2026 revenue guide to $875–$885M and adjusted EBITDA margin to 12–13%, with ~$549.6M in cash and marketable securities.
Broad commercial momentum across Zio Monitor and Zio AT, with expansion upstream into primary care (now a meaningful share of volume), 53% of volume via EHR integrations, and new-store growth accounting for ~64% of year‑over‑year volume gains.
Product and AI roadmap progressing — next‑generation AI 510(k) submitted and expected approval later this year, Zio MCT release reaffirmed for H1 2027, and the AI is expected to cut technician review time by ~50% and drive material margin/efficiency gains across the platform.
Regulatory and legal uncertainty remains — an FDA warning letter is still open despite remediation and a third‑party review with no material findings, the DOJ CID (focused on historical Zio AT periods) remains active, and the final CMS/MAC LCD outcome is uncertain.
International and adjacent market expansion is early — U.K. posted the company’s best quarter, Japan received a modest supplemental reimbursement (not yet meaningful), and sleep pilots are encouraging but unlikely to move the needle materially before 2027.

iRhythm Technologies Price Performance

IRTC traded down $8.36 on Friday, hitting $120.80. 1,336,081 shares of the company’s stock were exchanged, compared to its average volume of 389,157. iRhythm Technologies has a fifty-two week low of $112.31 and a fifty-two week high of $212.00. The company has a current ratio of 4.63, a quick ratio of 4.48 and a debt-to-equity ratio of 4.25. The firm has a 50-day moving average price of $122.93 and a 200-day moving average price of $154.60. The stock has a market cap of $3.97 billion, a price-to-earnings ratio of -86.29 and a beta of 1.18.

Trending Headlines about iRhythm Technologies

Here are the key news stories impacting iRhythm Technologies this week:

Positive Sentiment: Q1 results beat on revenue and EPS trends: iRhythm reported $199.4M in revenue (up 25.6% YoY) and a loss per share that was smaller than expected, indicating improving unit economics and topline momentum. This supports longer‑term growth expectations. IRTC Q1 results and call (MarketBeat)
Positive Sentiment: Needham raised its price target slightly to $255 and keeps a “buy” rating, signaling conviction from at least one growth‑oriented shop and providing a bullish anchor for longer‑term upside. Needham raises PT to $255 (Benzinga)
Neutral Sentiment: Company guidance: iRhythm issued FY2026 revenue guidance (~$875–$885M) roughly in line with consensus, which is steady but not clearly bullish; EPS guidance was not meaningfully changed. Guidance that meets expectations can temper upside momentum. IRTC Q1 financial results press release (GlobeNewswire)
Neutral Sentiment: Additional context available from the Q1 earnings call transcript and analyst previews/deep dives — useful for investors evaluating margin progression, reimbursement/regulatory updates and AI initiatives but not immediate price catalysts by themselves. Q1 earnings call transcript (Seeking Alpha)
Negative Sentiment: Analyst price‑target cuts from JPMorgan (PT lowered to $175 from $215) and Wells Fargo (PT lowered to $180 from $200) are exerting immediate downward pressure by reducing visible upside and prompting some investors to trim positions. JPMorgan & Wells Fargo lower PTs (Benzinga)
Negative Sentiment: Truist and other outlets flagged cuts to targets in their Q1 previews, adding to the sell‑side pushback; persistent negative margins and a negative return on equity keep valuation sensitive to near‑term profitability improvements. Truist cuts PT on IRTC (Yahoo Finance)

Insider Activity at iRhythm Technologies

In other news, EVP Sumi Shrishrimal sold 2,830 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $128.44, for a total transaction of $363,485.20. Following the transaction, the executive vice president owned 41,870 shares of the company’s stock, valued at approximately $5,377,782.80. The trade was a 6.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Minang Turakhia sold 4,027 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $128.45, for a total transaction of $517,268.15. Following the transaction, the executive vice president directly owned 54,906 shares in the company, valued at approximately $7,052,675.70. The trade was a 6.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 94,509 shares of company stock worth $12,734,195 over the last 90 days. Corporate insiders own 1.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Corient Private Wealth LLC boosted its position in shares of iRhythm Technologies by 12.1% during the 4th quarter. Corient Private Wealth LLC now owns 1,764 shares of the company’s stock valued at $313,000 after acquiring an additional 191 shares during the last quarter. Fuller & Thaler Asset Management Inc. boosted its position in shares of iRhythm Technologies by 7.4% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 639,423 shares of the company’s stock valued at $113,459,000 after acquiring an additional 44,175 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of iRhythm Technologies during the 4th quarter valued at about $855,000. RTW Investments LP acquired a new position in shares of iRhythm Technologies during the 4th quarter valued at about $209,732,000. Finally, Occudo Quantitative Strategies LP boosted its position in shares of iRhythm Technologies by 103.8% during the 4th quarter. Occudo Quantitative Strategies LP now owns 16,484 shares of the company’s stock valued at $2,925,000 after acquiring an additional 8,395 shares during the last quarter.

Analyst Ratings Changes

A number of analysts recently commented on IRTC shares. The Goldman Sachs Group lowered their target price on shares of iRhythm Technologies from $184.00 to $147.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of iRhythm Technologies in a research report on Tuesday, April 21st. Morgan Stanley reissued an “overweight” rating on shares of iRhythm Technologies in a research report on Monday, January 12th. Wells Fargo & Company reduced their price target on shares of iRhythm Technologies from $200.00 to $180.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Wall Street Zen lowered shares of iRhythm Technologies from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $197.77.

View Our Latest Stock Report on iRhythm Technologies

iRhythm Technologies Company Profile

(Get Free Report)

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.